GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pathfinder Cell Therapy Inc (OTCPK:PFND) » Definitions » Forward Dividend Yield %

Pathfinder Cell Therapy (Pathfinder Cell Therapy) Forward Dividend Yield % : 0.00% (As of Jun. 08, 2024)


View and export this data going back to . Start your Free Trial

What is Pathfinder Cell Therapy Forward Dividend Yield %?

As of today (2024-06-08), the Forward Annual Dividend Yield of Pathfinder Cell Therapy is 0.00%.

As of today (2024-06-08), the Trailing Annual Dividend Yield of Pathfinder Cell Therapy is 0.00%.

PFND's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.68
* Ranked among companies with meaningful Forward Dividend Yield % only.

Pathfinder Cell Therapy's Dividends per Share for the three months ended in Sep. 2015 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.


Competitive Comparison of Pathfinder Cell Therapy's Forward Dividend Yield %

For the Biotechnology subindustry, Pathfinder Cell Therapy's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pathfinder Cell Therapy's Forward Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pathfinder Cell Therapy's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Pathfinder Cell Therapy's Forward Dividend Yield % falls into.



Pathfinder Cell Therapy Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.


Pathfinder Cell Therapy  (OTCPK:PFND) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.


Pathfinder Cell Therapy Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Pathfinder Cell Therapy's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Pathfinder Cell Therapy (Pathfinder Cell Therapy) Business Description

Traded in Other Exchanges
N/A
Address
12 Bow Street, Cambridge, MA, USA, 02138
Pathfinder Cell Therapy Inc is a regenerative medicine company. It is engaged in developing novel cell-based and related therapies for the treatment of diabetes, renal diseases and medical conditions characterized by organ-specific cell damage. Further, the group has discovered a new mammalian cell type, which is able to stimulate damaged tissues to regenerate without the Pathfinder Cells ("PCs") themselves being incorporated into the new tissue. Geographically the business activities are functioned through the region of United States.
Executives
John J Alam director 130 WAVERLY STREET, CAMBRIDGE MA 02139
John L Brooks director 100 LOWDER BROOK DRIVE SUITE 2500, WESTWOOD MA 02090

Pathfinder Cell Therapy (Pathfinder Cell Therapy) Headlines

No Headlines